Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39,719 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Wildsmith S, Li W, Wu S, Stewart R, Morsli N, Raja R, Zhang Q, Ye J, He P, Shetty J, Yovine A, Holoweckyj N, Real K, Walker J, Wrona M, de Los Reyes M, Barker C, Whiteley J, Haddad R, Licitra L, Ferris R, Fayette J, Zandberg DP, Siu LL, Mesía R. Wildsmith S, et al. Among authors: wu s. Clin Cancer Res. 2023 Jun 1;29(11):2066-2074. doi: 10.1158/1078-0432.CCR-22-2765. Clin Cancer Res. 2023. PMID: 36806911 Free PMC article. Clinical Trial.
Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial.
Garon EB, Spira AI, Goldberg SB, Chaft JE, Papadimitrakopoulou V, Cascone T, Antonia SJ, Brahmer JR, Camidge DR, Powderly JD, Wozniak AJ, Felip E, Wu S, Ascierto ML, Elgeioushi N, Awad MM. Garon EB, et al. Among authors: wu s. J Thorac Oncol. 2023 Aug;18(8):1094-1102. doi: 10.1016/j.jtho.2023.04.020. Epub 2023 May 4. J Thorac Oncol. 2023. PMID: 37146752 Free article. Clinical Trial.
Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners.
Doshi AS, Cantin S, Hernandez M, Srinivasan S, Tentarelli S, Griffin M, Wang Y, Pop-Damkov P, Prickett LB, Kankkonen C, Shen M, Martin MS, Wu S, Castaldi MP, Ghadially H, Varnes J, Gales S, Henry D, Hoover C, Mele DA, Simpson I, Gangl ET, Mlynarski SN, Finlay MRV, Drew L, Fawell SE, Shao W, Schuller AG. Doshi AS, et al. Among authors: wu s. Mol Cancer Ther. 2023 May 4;22(5):630-645. doi: 10.1158/1535-7163.MCT-22-0431. Mol Cancer Ther. 2023. PMID: 36912782
39,719 results
You have reached the last available page of results. Please see the User Guide for more information.